March 2026 – As the first quarter of 2026 draws to a close, METAvivor, the leading advocate for those living with metastatic breast cancer (MBC), is navigating a complex and volatile legislative environment. From the halls of Congress to the intricacies of national cancer registries, the organization is doubling down on its mission to secure life-saving research funding, enhance federal transparency, and empower its nationwide network of advocates. This monthly update provides a comprehensive overview of the current policy landscape, the outcomes of the recent GroundSwell virtual advocacy campaign, and the strategic initiatives planned for the coming months.
The Fiscal Year 2027 Appropriations Landscape: A High-Stakes Battle
The federal budget process for Fiscal Year 2027 (FY27) has officially commenced, and METAvivor is at the forefront of the conversation. With the President’s Budget proposal anticipated in late March, the organization has proactively submitted formal recommendations to the House and Senate Appropriations Committees.
The Fight for DoD Breast Cancer Research
A cornerstone of METAvivor’s current legislative agenda is the restoration and expansion of funding for the Department of Defense’s (DoD) Breast Cancer Research Program (BCRP). METAvivor has issued a direct appeal to appropriators to secure $150 million for the BCRP in the FY27 cycle. This request represents a $5 million increase over the FY26 enacted levels, aiming to restore the program to its FY24 benchmarks.
The rationale behind this push is rooted in the unique, high-impact nature of the DoD program, which often funds innovative, high-risk research that traditional granting bodies may overlook. By collaborating with a broader coalition of patient advocacy groups, providers, and research institutions, METAvivor aims to leverage collective strength to ensure that MBC research remains a priority in an increasingly crowded fiscal landscape.
Legislative Gridlock and the Shadow of DHS Appropriations
While the FY27 process is moving forward, the legislative branch remains bogged down by unresolved issues from the previous fiscal cycle. The Department of Homeland Security (DHS) remains at the center of a protracted funding stalemate.
The ongoing partial government shutdown—which has impacted entities like the U.S. Coast Guard, the TSA, and the Secret Service since mid-February—continues to create an atmosphere of instability in Washington. While the Immigration and Customs Enforcement (ICE) agency was insulated from this stalemate due to funding allocated in earlier legislative packages, the broader disagreement surrounding DHS, combined with the escalating financial demands of ongoing global conflicts, such as the war in Iran, is expected to cast a long shadow over the FY27 appropriations debate. METAvivor’s leadership is closely monitoring these developments, as the timing and tone of the upcoming budget negotiations are likely to be heavily influenced by these external pressures.
NIH Oversight and the Future of Grant Funding
On March 17, the House Appropriations Committee’s Subcommittee on Labor, Health and Human Services, Education, and Related Agencies (LHHS) held a pivotal oversight hearing regarding the National Institutes of Health (NIH). NIH Director Jay Bhattacharya, who has also been tapped by the Administration to serve as Acting Director of the CDC, testified before lawmakers on the agency’s future trajectory.
Key Testimony and Policy Shifts
Dr. Bhattacharya offered several key assurances to the subcommittee:
- Grant Timelines: The NIH has committed to awarding all grant funding for the 2026 fiscal year by year-end, with the National Cancer Institute (NCI) actively accelerating its approval processes to meet this mandate.
- Political Neutrality: Addressing concerns regarding the politicization of science, Dr. Bhattacharya pledged to safeguard the integrity of the research enterprise from outside influence.
- Legislative Scrutiny: Members of the committee from both sides of the aisle expressed varied concerns. Republicans focused on restoring public trust in scientific institutions and ensuring equitable geographic distribution of funds. Conversely, Democrats emphasized the protection of scientific merit in grant-making and the necessity of supporting diversity and early-career investigators.
A significant point of contention raised by Ranking Member Rosa DeLauro (D-CT) concerned the practice of "forward-funding"—the front-loading of payments for multi-year research grants. Critics argue that this practice has led to a significant decrease in new awards, with 2,000 fewer grants in 2025 and an acceptance rate of less than 10% for NCI research applications. In response, the FY26 funding bill includes strict limitations on forward-funding, a policy shift that METAvivor will continue to track to ensure it does not inadvertently stifle progress in metastatic breast cancer research.
GroundSwell 2026: A Milestone in Virtual Advocacy
METAvivor’s third annual GroundSwell Virtual Advocacy Event, which launched on February 23, concluded in mid-March after a two-week extension. The extension was granted to accommodate the high volume of interest from advocates seeking to schedule meetings with their respective Congressional representatives.
Event Impact and Preliminary Feedback
More than 100 advocates participated in this year’s event, marking a significant milestone in METAvivor’s grassroots strategy. The organization is currently in the process of reviewing post-meeting survey forms to gauge the efficacy of the sessions. This data will be instrumental in refining the curriculum and logistics for future initiatives, including the "Stampede" event slated for the fall and the 2027 iteration of GroundSwell. By fostering direct communication between patients and policymakers, GroundSwell serves as a critical bridge, humanizing the statistics of MBC and ensuring that the lived experience of patients is represented in federal policy.
Strengthening the SEER Strategy: Data-Driven Advocacy
Beyond direct lobbying, METAvivor is investing heavily in the infrastructure of cancer data. The organization is currently deepening its collaboration with the North American Association of Central Cancer Registries (NAACCR) and the National Cancer Registrar’s Association (NCRA).
These partnerships are focused on better understanding and modernizing the NCI’s SEER (Surveillance, Epidemiology, and End Results) Cancer Registry and the CDC’s National Program for Cancer Registries (NCPR). By tapping into the expertise of these associations, METAvivor aims to:
- Improve Data Accuracy: Ensure that metastatic breast cancer is accurately reflected in national datasets.
- Modernize Systems: Advocate for technical upgrades that allow for more granular, up-to-date tracking of MBC outcomes.
- Enhance Representation: Ensure that the diverse experiences of all MBC patients are captured, providing a more robust foundation for evidence-based policymaking.
Digital Empowerment: The Launch of VoterVoice
In a move to modernize its e-advocacy capabilities, the METAvivor Board of Directors has approved the implementation of "VoterVoice," a comprehensive advocacy software platform. This system is designed to streamline the engagement process for advocates nationwide.
Features and Strategic Benefits
VoterVoice will provide METAvivor supporters with:
- Direct Access: A simplified portal to identify Congressional representatives based on user location.
- Personalized Communication: Access to staff-curated draft letters that can be sent instantly or customized to reflect individual patient stories.
- Data-Driven Insights: The tool will provide the advocacy team with real-time analytics regarding engagement levels, geographic hotspots of support, and the issues that resonate most deeply with the community.
This digital transformation represents a major step forward in METAvivor’s ability to mobilize its base quickly and effectively in response to rapidly changing legislative environments.
Looking Ahead: The April Agenda
As METAvivor transitions into April, the organization’s agenda is clearly defined by several high-priority goals:
- GroundSwell Wrap-up: Finalizing the reporting and feedback loops from the virtual advocacy event to prepare for future programming.
- Appropriations Advocacy: Maintaining consistent pressure on Congress to ensure the $150 million BCRP funding target remains a focal point of the FY27 budget.
- Legislative Promotion: Actively promoting the Senate introduction of the Cancer Drug Parity Act, a crucial bill for improving access to treatment for patients.
- Strategic Expansion: Continuing the development of the SEER/NCPR strategy and the full-scale launch of the VoterVoice platform.
The METAvivor Advocacy Team remains committed to transparency and community engagement. By synthesizing expert research, direct grassroots action, and modern digital tools, the organization continues to make significant strides toward a future where metastatic breast cancer is not just treated, but fully understood and effectively addressed through proactive federal policy.
For more information on how to get involved in upcoming advocacy efforts, please visit the official METAvivor website or contact the advocacy department directly.
About the Author
